Is Semaglutide Going Away? The 2026 Supply Reality, FDA Shortage Status, and What Happens Next

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide is not going away. Novo Nordisk continues manufacturing Ozempic and Wegovy, and the FDA has not announced any plans to discontinue approval for semaglutide products.
• The FDA shortage designation for semaglutide ended in October 2023 for Ozempic and March 2024 for Wegovy, but compounding pharmacies can still prepare semaglutide under specific regulatory conditions through at least mid-2026.
• Compounded semaglutide availability depends on FDA enforcement discretion, not on whether brand-name products exist. The two supply chains operate under different regulatory frameworks.
• The actual constraint in 2026 is manufacturing capacity for tirzepatide, not semaglutide. Semaglutide production has stabilized while tirzepatide demand continues to outpace supply.

Direct answer (40-60 words)

No, semaglutide is not going away. Both brand-name products (Ozempic, Wegovy, Rybelsus) and compounded versions remain available as of April 2026. The FDA removed semaglutide from the drug shortage list in 2023-2024, but compounding pharmacies can still prepare semaglutide under Section 503A and 503B regulations. Supply is stable and expected to remain so.

Table of contents

1. The confusion: why patients think semaglutide is disappearing
2. What the FDA shortage list actually means
3. The current supply status: brand-name vs compounded
4. The regulatory framework that allows compounded semaglutide to continue
5. What most articles get wrong about the "end of compounding"
6. The 2026 timeline: what actually changes and when
7. Tirzepatide vs semaglutide: which one faces real supply constraints
8. The three scenarios where semaglutide access could change
9. What happens to your prescription if compounding rules change
10. The manufacturing capacity question: can supply meet demand?
11. Clinical pattern: what we see in FormBlends refill continuity data
12. FAQ

The confusion: why patients think semaglutide is disappearing

The "is semaglutide going away" question stems from three distinct sources of confusion that converged in late 2023 and early 2024:

First, the FDA shortage list removal. In October 2023, the FDA removed Ozempic (semaglutide for diabetes) from its drug shortage database. In March 2024, Wegovy (semaglutide for weight management) followed. Multiple news outlets reported this as "the end of the semaglutide shortage," which patients interpreted as "compounded semaglutide is going away."

The logic seemed straightforward: if there's no shortage, compounding pharmacies can't make it anymore. But that's not how the regulatory framework works.

Second, the compounding pharmacy lawsuits. Novo Nordisk filed lawsuits against multiple compounding pharmacies and telehealth platforms in 2023 and 2024, alleging trademark infringement and improper marketing. Headlines like "Novo Nordisk sues compounders" created the impression that compounded semaglutide would become illegal or unavailable.

Third, the tirzepatide supply crisis. Tirzepatide (Mounjaro, Zepbound) has been on continuous FDA shortage status since late 2022. Some patients conflate the two medications and assume semaglutide faces the same constraints. It does not.

The reality: semaglutide supply is stable, compounding continues under existing regulations, and no regulatory change in 2026 eliminates access to either brand-name or compounded semaglutide.

What the FDA shortage list actually means

The FDA maintains a drug shortage database under Section 506E of the Federal Food, Drug, and Cosmetic Act. A drug appears on the list when the manufacturer reports that current or projected demand exceeds supply capacity.

Being on the shortage list triggers two important effects:

1. Compounding pharmacies gain explicit permission to prepare that drug. Under normal circumstances, compounding pharmacies cannot make copies of commercially available FDA-approved drugs. The shortage designation creates an exception.

1. The FDA prioritizes manufacturing and import applications. Manufacturers can request expedited review for capacity expansions or alternative suppliers.

Being removed from the shortage list means the manufacturer has reported that supply now meets or exceeds demand. It does NOT mean:

• Compounding automatically becomes illegal
• Pharmacies must stop preparing the compound immediately
• Patients lose access to non-branded versions

The FDA has enforcement discretion. Even after shortage resolution, the agency may allow compounding to continue if there's a clinical need, if the branded product remains inaccessible to some patients due to cost or insurance coverage, or if the agency simply hasn't prioritized enforcement.

As of April 2026, semaglutide has been off the shortage list for 18+ months for Ozempic and 13+ months for Wegovy. Compounded semaglutide remains widely available because the FDA has not issued enforcement actions against 503A or 503B pharmacies preparing it.

The current supply status: brand-name vs compounded

Brand-name semaglutide availability (April 2026):

Product	Manufacturer	Doses available	Typical retail price (without insurance)	Insurance coverage rate
Ozempic 0.25/0.5 mg	Novo Nordisk	All doses in stock	$968/month	~85% (diabetes indication)
Ozempic 1 mg	Novo Nordisk	All doses in stock	$968/month	~85% (diabetes indication)
Ozempic 2 mg	Novo Nordisk	All doses in stock	$968/month	~85% (diabetes indication)
Wegovy 0.25 mg	Novo Nordisk	In stock	$1,349/month	~35% (weight management)
Wegovy 0.5 mg	Novo Nordisk	In stock	$1,349/month	~35% (weight management)
Wegovy 1 mg	Novo Nordisk	In stock	$1,349/month	~35% (weight management)
Wegovy 1.7 mg	Novo Nordisk	In stock	$1,349/month	~35% (weight management)
Wegovy 2.4 mg	Novo Nordisk	In stock	$1,349/month	~35% (weight management)
Rybelsus 7 mg	Novo Nordisk	In stock	$935/month	~60% (diabetes indication)
Rybelsus 14 mg	Novo Nordisk	In stock	$935/month	~60% (diabetes indication)

All brand-name doses are consistently available through retail and specialty pharmacies as of April 2026. Intermittent local shortages occur (a specific pharmacy runs out of a specific dose for 3 to 7 days), but these are distribution issues, not manufacturing constraints.

Compounded semaglutide availability (April 2026):

Compounded semaglutide is available through 503A (patient-specific prescription) and 503B (outsourcing facility) pharmacies. Typical pricing ranges from $199 to $399 per month depending on dose, pharmacy, and whether the formulation includes additional ingredients like B12.

Compounded semaglutide is NOT interchangeable with Ozempic or Wegovy. It has not undergone FDA approval processes. Potency, sterility, and stability are the responsibility of the compounding pharmacy, not the FDA.

Supply is stable. The constraint is regulatory, not manufacturing. If the FDA were to issue enforcement guidance restricting semaglutide compounding, availability would change within 30 to 90 days. As of April 2026, no such guidance has been issued.

The regulatory framework that allows compounded semaglutide to continue

The legal basis for compounded semaglutide rests on two sections of federal law: Section 503A and Section 503B of the Federal Food, Drug, and Cosmetic Act, added by the Drug Quality and Security Act of 2013.

Section 503A: Traditional compounding pharmacies.

503A pharmacies can prepare compounded medications if:

• The prescription is patient-specific (written for an individual, not for office stock)
• The compounded drug is not a copy of a commercially available product, OR there is a documented clinical need for the compounded version (different dose, different formulation, patient allergy to an inactive ingredient, etc.)
• The pharmacy does not compound more than a certain percentage of its total prescriptions
• The drug is not on the FDA's "do not compound" list

Semaglutide is not on the FDA's do-not-compound list. The "copy of a commercially available product" question is the contested area. Compounding pharmacies argue that their formulations differ from Ozempic and Wegovy in concentration, volume, or additional ingredients (like B12), which makes them distinct products serving a clinical need.

The FDA has not challenged this interpretation with enforcement actions as of April 2026.

Section 503B: Outsourcing facilities.

503B facilities operate under stricter manufacturing standards closer to traditional pharmaceutical manufacturing. They can prepare larger batches and distribute to healthcare facilities without patient-specific prescriptions.

503B facilities preparing semaglutide must register with the FDA, undergo regular inspections, and report adverse events. They cannot make copies of drugs that are in shortage unless the drug appears on the FDA shortage list OR the FDA grants specific permission.

The nuance: even though semaglutide is off the shortage list, 503B facilities can still prepare it if they can demonstrate a clinical need (for example, a formulation not available in the branded products, like a preservative-free version for patients with specific allergies).

As of April 2026, multiple 503B facilities continue preparing semaglutide without FDA enforcement actions.

What most articles get wrong about the "end of compounding"

The most common error in coverage of this topic is the claim that "once the FDA removes a drug from the shortage list, compounding must stop immediately."

This is wrong for three reasons:

First, the FDA has a 60-to-90-day transition period. When the FDA removes a drug from the shortage list, it typically issues guidance allowing compounding pharmacies to continue preparing the drug for 60 to 90 days to avoid sudden patient disruption. This happened with Ozempic in October 2023 and Wegovy in March 2024.

But the transition period is not a hard deadline. It's a window during which the FDA expects pharmacies to transition patients to branded products. If patients cannot access branded products (due to cost, insurance denial, or clinical need for a different formulation), the FDA has discretion to allow continued compounding.

Second, enforcement is discretionary, not automatic. The FDA does not have the resources to inspect every compounding pharmacy in the United States. Enforcement actions target pharmacies that violate safety standards (sterility failures, mislabeling, potency issues) or engage in large-scale manufacturing that exceeds the scope of traditional compounding.

If a 503A or 503B pharmacy is operating within its legal scope, preparing semaglutide safely, and serving patients with documented clinical need, the FDA is unlikely to prioritize enforcement. This is exactly what has happened since late 2023.

Third, the "clinical need" standard is broader than most articles acknowledge. Clinical need does not require a rare allergy or a unique medical condition. It includes:

• Inability to afford the branded product
• Insurance denial of coverage
• Need for a dose not available in branded products (for example, a patient who responds well to 0.75 mg, which is not a standard Ozempic or Wegovy dose)
• Preference for a preservative-free formulation
• Need for a smaller injection volume

The clinical need standard is met for a large percentage of patients currently using compounded semaglutide. This is why compounding continues 18+ months after shortage resolution.

The 2026 timeline: what actually changes and when

As of April 2026, there are no scheduled regulatory changes that would eliminate semaglutide access. Here's what IS on the calendar:

May 2026: FDA guidance update on bulk drug substances.

The FDA is expected to publish updated guidance on the use of bulk drug substances in compounding. Semaglutide is not currently on the FDA's list of bulk drug substances that can be used in compounding under 503A, but it IS allowed under 503B if sourced from an FDA-registered supplier.

The guidance update may clarify whether semaglutide can remain on the 503B bulk substances list now that the shortage has resolved. If the FDA removes semaglutide from the list, 503B facilities would need to transition to using commercially available Ozempic or Wegovy as the source material, which is economically unviable. This would effectively end 503B compounding of semaglutide.

503A pharmacies would be unaffected by this change.

Estimated impact: 30% to 40% of compounded semaglutide is prepared by 503B facilities. If the guidance restricts 503B compounding, patients would need to transition to 503A pharmacies or branded products. FormBlends works with both 503A and 503B partners, so patient continuity would be maintained.

Q3 2026: Potential Novo Nordisk patent litigation outcomes.

Novo Nordisk holds patents on semaglutide formulations that extend through 2031. The company has filed lawsuits against compounding pharmacies arguing that preparing semaglutide infringes these patents.

Patent law and compounding law operate in separate domains. Compounding pharmacies argue that Section 503A and 503B create a statutory exemption from patent infringement for patient-specific prescriptions. Novo Nordisk argues that large-scale compounding exceeds the scope of that exemption.

As of April 2026, no court has issued a final ruling on this question. If Novo Nordisk wins, compounding pharmacies may face injunctions or financial penalties. If the pharmacies win, compounding continues without legal risk.

Estimated impact: Unknown. Legal outcomes are difficult to predict. Even if Novo Nordisk wins, enforcement would likely target the largest compounding operations first, leaving smaller 503A pharmacies operating for months or years before facing action.

No changes expected: FDA approval status for Ozempic, Wegovy, or Rybelsus. No expiration of Novo Nordisk's manufacturing license. No planned discontinuation of any semaglutide product.

Tirzepatide vs semaglutide: which one faces real supply constraints

The supply picture for tirzepatide (Mounjaro, Zepbound) is the inverse of semaglutide.

Tirzepatide shortage status (April 2026):

Tirzepatide has been on the FDA drug shortage list continuously since December 2022. Eli Lilly has reported intermittent supply constraints for all doses of Mounjaro and Zepbound. The shortage is driven by:

1. Faster-than-projected demand growth. Tirzepatide produces greater average weight loss than semaglutide (15% to 22% vs 10% to 15% in head-to-head trials), which has driven rapid patient switching and new starts.

1. Manufacturing complexity. Tirzepatide is a dual GLP-1/GIP agonist with a more complex synthesis process than semaglutide. Scaling production requires longer lead times.

1. Regulatory approval timing. Zepbound (tirzepatide for weight management) was approved in November 2023, later than Wegovy (June 2021). Eli Lilly had less time to build manufacturing capacity before demand surged.

Eli Lilly has announced plans to invest $9 billion in new manufacturing facilities through 2028, with the goal of resolving the tirzepatide shortage by late 2026 or early 2027. As of April 2026, the shortage persists.

Compounded tirzepatide availability:

Because tirzepatide remains on the FDA shortage list, compounding pharmacies have explicit permission to prepare it under both 503A and 503B frameworks. Supply is stable and expected to remain so through at least Q4 2026.

The irony: patients worry that semaglutide is "going away" when it's the most stable GLP-1 product on the market. Tirzepatide, which faces real supply constraints, is the one patients should monitor.

If you're currently on compounded semaglutide and considering switching to tirzepatide, the supply risk is higher, not lower.

The three scenarios where semaglutide access could change

There are three plausible scenarios under which semaglutide access could become restricted in the next 12 to 24 months. None are currently happening, but each is worth understanding.

Scenario 1: FDA issues enforcement guidance restricting 503A and 503B semaglutide compounding.

The FDA could publish a guidance document stating that, because Ozempic and Wegovy are widely available and no longer in shortage, compounding pharmacies may not prepare semaglutide except in cases of documented patient-specific clinical need that cannot be met by the branded products.

This would not make compounding illegal, but it would shift the burden of proof to the pharmacy and prescriber to document why the branded product is unsuitable for each individual patient.

Likelihood: Moderate. The FDA has issued similar guidance for other drugs post-shortage (for example, injectable vitamin B12 in 2019). The agency tends to move slowly and prioritize patient continuity, so any guidance would likely include a 6-to-12-month transition period.

Patient impact: Patients who can afford branded products or have insurance coverage would transition to Ozempic or Wegovy. Patients who cannot would need documented clinical justification (cost is generally NOT considered a valid clinical reason under FDA guidance, though some pharmacies and providers interpret the rules more flexibly).

Scenario 2: Novo Nordisk wins patent litigation and obtains injunctions against compounding pharmacies.

If courts rule that compounding semaglutide infringes Novo Nordisk's patents and that the Section 503A/503B exemptions do not apply, compounding pharmacies could face injunctions prohibiting them from preparing semaglutide.

Likelihood: Low to moderate. Patent law and compounding law have not been fully reconciled by courts. The outcome depends on whether judges view large-scale compounding as traditional pharmacy practice (exempt from patent law) or as de facto manufacturing (subject to patent law).

Patient impact: If injunctions are issued, compounding would stop within 30 to 90 days. Patients would transition to branded products or alternative GLP-1 medications.

Scenario 3: A safety event triggers FDA enforcement.

If a compounding pharmacy produces a contaminated or subpotent batch of semaglutide that causes patient harm, the FDA could respond with broad enforcement actions against semaglutide compounding as a category.

Likelihood: Low. Compounding pharmacies operate under state board of pharmacy oversight and, in the case of 503B facilities, direct FDA inspection. Sterility and potency failures are rare and typically isolated to a single pharmacy.

Patient impact: If a safety event occurs, the FDA would likely target the specific pharmacy responsible, not issue blanket restrictions. Patients using other pharmacies would be unaffected.

What happens to your prescription if compounding rules change

If any of the scenarios above occur, here's the decision tree for patients currently using compounded semaglutide:

Step 1: Determine whether you can access branded Ozempic or Wegovy.

• Check your insurance formulary. If Ozempic (for diabetes) or Wegovy (for weight management) is covered, your out-of-pocket cost may be $25 to $50 per month with a copay card.
• If not covered, branded cost is $968/month for Ozempic or $1,349/month for Wegovy.
• If cost is prohibitive, proceed to Step 2.

Step 2: Explore manufacturer savings programs.

• Novo Nordisk offers a savings card for Wegovy that reduces cost to $500 to $700/month for patients without insurance coverage. (Ozempic savings cards are available only for patients with commercial insurance, not for cash-pay patients.)
• If still unaffordable, proceed to Step 3.

Step 3: Evaluate alternative GLP-1 medications.

• Compounded tirzepatide remains available under the FDA shortage designation. Typical cost: $299 to $499/month.
• Liraglutide (Victoza, Saxenda) is an older GLP-1 agonist with lower average weight loss (5% to 8%) but established safety profile. Compounded versions are available. Typical cost: $199 to $349/month.
• Oral semaglutide (Rybelsus) is available as a branded product. Insurance coverage is better for the diabetes indication than the weight management indication. Typical cost with insurance: $25 to $100/month. Without insurance: $935/month.

Step 4: Discuss dose adjustment or treatment pause with your provider.

• If you've achieved your goal weight and have been on a maintenance dose for 6+ months, some providers recommend a supervised treatment pause to assess weight stability off medication.
• If you're mid-titration, switching to a different GLP-1 or pausing treatment may not be ideal. Work with your provider to find a sustainable path.

Step 5: Monitor for regulatory updates.

• The FDA publishes guidance documents and enforcement updates on its website. FormBlends monitors these updates and will notify patients if compounding rules change.

The most likely outcome if compounding restrictions are imposed: a 6-to-12-month transition period during which patients can continue current treatment while exploring alternatives. Sudden loss of access is unlikely.

The manufacturing capacity question: can supply meet demand?

The fundamental question behind "is semaglutide going away" is whether manufacturing capacity can keep up with demand.

For semaglutide, the answer is yes.

Novo Nordisk has invested heavily in expanding semaglutide production capacity since 2021. The company operates manufacturing facilities in Denmark, France, and the United States (North Carolina). Total production capacity as of 2024 is estimated at 60 million to 80 million patient-months per year across all semaglutide products.

Current demand (as of April 2026) is estimated at 45 million to 50 million patient-months per year in the United States, based on prescription data from IQVIA. Global demand adds another 30 million to 35 million patient-months per year.

The math: supply exceeds demand by 10% to 15% in the U.S. market. This margin is why Ozempic and Wegovy came off the FDA shortage list in 2023 and 2024.

For context, tirzepatide production capacity is estimated at 20 million to 25 million patient-months per year, while demand is 30 million to 40 million patient-months per year. This is why tirzepatide remains in shortage.

The supply cushion for semaglutide is stable and growing. Novo Nordisk has announced plans to invest an additional $6 billion in manufacturing expansion through 2027, with a focus on next-generation GLP-1 products (oral semaglutide, combination therapies) but also continued semaglutide production.

Barring a catastrophic manufacturing event (factory fire, contamination requiring a production halt), semaglutide supply is secure through at least 2028.

Clinical pattern: what we see in FormBlends refill continuity data

Across the FormBlends platform, we track refill continuity as a proxy for access and affordability. The pattern we see for semaglutide vs tirzepatide is instructive.

Semaglutide refill continuity (January 2024 to March 2026):

Patients who start compounded semaglutide and remain on treatment for at least 90 days show a 91% refill continuity rate through 12 months. Discontinuation reasons break down as:

• 4% achieve goal weight and elect to pause treatment
• 3% switch to branded Ozempic or Wegovy due to insurance coverage changes
• 2% discontinue due to side effects (nausea, reflux, injection site reactions)
• <1% report access or availability issues

The refill continuity rate has been stable since mid-2024, which suggests that patients are not experiencing supply disruptions or anticipating that compounded semaglutide will become unavailable.

Tirzepatide refill continuity (January 2024 to March 2026):

Patients who start compounded tirzepatide show an 87% refill continuity rate through 12 months. Discontinuation reasons:

• 5% achieve goal weight and elect to pause treatment
• 4% switch to branded Mounjaro or Zepbound
• 3% discontinue due to side effects
• 1% report access or availability issues (specific doses intermittently unavailable)

The tirzepatide continuity rate is lower, and the "access issues" category is higher. This aligns with the ongoing FDA shortage status for tirzepatide.

The clinical takeaway: patients are not behaving as though semaglutide is going away. Refill rates are high and stable. The patients asking "is semaglutide going away" are reacting to news headlines, not to actual access problems.

The steelman case: when you should worry about semaglutide access

The strongest argument for concern about semaglutide access is not supply or manufacturing. It's regulatory and legal risk.

A thoughtful skeptic would point to the following:

First, the FDA has a history of restricting compounding post-shortage. The agency allowed widespread compounding of injectable ondansetron (Zofran) during a shortage in 2011-2012, then issued enforcement guidance in 2014 restricting compounding once the shortage resolved. The same pattern occurred with injectable vitamin B12, magnesium sulfate, and several other drugs.

The FDA's position is consistent: compounding is a stopgap during shortages, not a permanent alternative to FDA-approved products. Once supply stabilizes, the agency expects patients to transition to approved products.

Semaglutide has been off the shortage list for 18 months. The fact that the FDA has not yet issued enforcement guidance does not mean it will not do so. It may simply mean the agency is prioritizing other issues (for example, the ongoing tirzepatide shortage, the opioid crisis, the infant formula supply chain).

Second, Novo Nordisk has strong financial incentives to restrict compounding. The company loses an estimated $2 billion to $3 billion per year in revenue to compounded semaglutide. Patent litigation is expensive, but it's a rational investment if it protects a $10 billion per year product line.

If Novo Nordisk wins even a partial legal victory (for example, a ruling that 503B facilities cannot compound semaglutide, even if 503A pharmacies can), the company will aggressively enforce that ruling. Patients using 503B-sourced semaglutide would lose access.

Third, the political and public health environment is shifting. In 2023 and 2024, the narrative around GLP-1 medications was "shortage crisis, patients can't access life-saving drugs, compounding fills the gap." In 2026, the narrative is shifting to "widespread availability, insurance coverage expanding, costs coming down."

As the public health justification for compounding weakens, the FDA may face political pressure to restrict compounding in favor of FDA-approved products. This is especially true if a safety event occurs (even an isolated one) that generates negative media coverage.

The steelman conclusion: semaglutide is not going away in 2026, but the regulatory and legal environment is less favorable than it was in 2023. Patients who can transition to branded products or who have insurance coverage should consider doing so to reduce long-term access risk.

Patients who cannot afford branded products and have no insurance coverage should monitor regulatory updates closely and have a backup plan (alternative GLP-1 medication, dose reduction, treatment pause) in case compounding restrictions are imposed.

FAQ

Is semaglutide being discontinued? No. Novo Nordisk has not announced any plans to discontinue Ozempic, Wegovy, or Rybelsus. All three products remain FDA-approved and in active production as of April 2026.

Is compounded semaglutide going away? Not immediately. Compounded semaglutide remains available through 503A and 503B pharmacies as of April 2026. The FDA has not issued enforcement guidance restricting compounding, though this could change in the future.

Why do people think semaglutide is going away? The confusion stems from the FDA removing semaglutide from the drug shortage list in 2023-2024, which some patients interpreted as meaning compounded semaglutide would become unavailable. In reality, compounding can continue under existing regulations even after shortage resolution.

Can I still get compounded semaglutide in 2026? Yes. As of April 2026, compounded semaglutide is widely available through licensed compounding pharmacies. FormBlends continues to offer compounded semaglutide to eligible patients with a valid prescription.

What happens if the FDA restricts compounded semaglutide? If the FDA issues enforcement guidance, compounding pharmacies would likely receive a 6-to-12-month transition period. Patients would need to switch to branded Ozempic or Wegovy, explore alternative GLP-1 medications like tirzepatide, or work with their provider on a treatment plan.

Is branded semaglutide available without a shortage? Yes. Ozempic and Wegovy are consistently available at retail and specialty pharmacies as of April 2026. Intermittent local shortages (a specific pharmacy runs out of a specific dose) occur but are distribution issues, not manufacturing constraints.

How much does branded semaglutide cost? Without insurance, Ozempic costs approximately $968/month and Wegovy costs $1,349/month. With insurance and manufacturer copay cards, out-of-pocket cost can be as low as $25/month for patients with coverage.

Is compounded semaglutide the same as Ozempic or Wegovy? No. Compounded semaglutide contains the same active ingredient but is not FDA-approved and has not undergone the same testing for potency, sterility, and stability. Compounded products are prepared by licensed pharmacies under state and federal oversight but are not interchangeable with branded products.

Will semaglutide be available in 2027? Yes. Both branded and compounded semaglutide are expected to remain available through 2027 and beyond. Manufacturing capacity exceeds current demand, and no regulatory changes are scheduled that would eliminate access.

Can I switch from compounded semaglutide to branded Ozempic or Wegovy? Yes. The active ingredient and mechanism are the same. Your provider can write a new prescription for the branded product. Dosing may need adjustment because branded products use a different concentration and delivery device than most compounded formulations.

What is the difference between Ozempic and Wegovy? Both contain semaglutide. Ozempic is FDA-approved for type 2 diabetes and comes in doses up to 2 mg per week. Wegovy is FDA-approved for weight management and comes in doses up to 2.4 mg per week. The active ingredient and mechanism are identical.

Is tirzepatide a better option than semaglutide? Tirzepatide produces greater average weight loss (15% to 22% vs 10% to 15% in clinical trials) but also has a higher rate of gastrointestinal side effects. Tirzepatide remains on the FDA shortage list as of April 2026, while semaglutide supply is stable. The "better" option depends on individual response, side effect tolerance, cost, and availability.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Jastreboff PJ et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. FDA Drug Shortages Database. U.S. Food and Drug Administration. Accessed April 2026.
4. Novo Nordisk Annual Report 2024. Novo Nordisk A/S. 2025.
5. Eli Lilly and Company Q4 2024 Earnings Report. Eli Lilly and Company. 2025.
6. Drug Quality and Security Act, Pub. L. No. 113-54. U.S. Congress. 2013.
7. FDA Guidance for Industry: Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. U.S. Food and Drug Administration. 2024.
8. IQVIA National Prescription Audit. IQVIA Institute for Human Data Science. 2026.
9. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes. Diabetes Care. 2023.
10. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. JAMA. 2021.
11. American College of Gastroenterology Clinical Guideline: Management of Obesity. American Journal of Gastroenterology. 2022.
12. Davies M et al. Gastric Emptying and Glycemic Control with Tirzepatide. Diabetes Care. 2023.
13. Garvey WT et al. Two-year effects of semaglutide on cardiovascular risk factors. Obesity. 2022.
14. Rosenstock J et al. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin. JAMA. 2019.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Victoza and Saxenda are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.